GLAND PHARMA LIMITED

November 12, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Para B of Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), it is hereby informed that Gland Pharma Limited ("Company") has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company.

The details required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in **Annexure A** enclosed herewith.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Pallerlamudi Sampath Kumar
Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.11.12 17:10:28 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: Annexure A

Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

SI. No	Particulars	Remarks
1	name of party for which such guarantees or indemnity or surety was given;	Phixen SAS, wholly owned step down subsidiary of the Company.
2	whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
3	brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee	Phixen SAS has entered into a Uncommitted Revolving Facility ('Facility') Agreement with MUFG Bank (Europe) N.V. ("MUFG Bank") for Euro 50 Mn with an initial draw-down limit of Euro 18 Mn. Against this initial draw - down Limit, Gland Pharma has extended a Corporate Guarantee of EURO 20 Mn in favour of MUFG Bank to secure the draw-down amount and interest thereon. The Company may extend the Limit of Corporate Guarantee in favour of MUFG Bank, if the draw-down Limits to Phixen SAS increases, in the future. The same will be informed to the Stock Exchanges accordingly. The Facility Agreement is valid for 3 years, and the Corporate Guarantee is valid till March 31, 2030.
4	impact of such guarantees or indemnity or surety on listed entity	The Corporate Guarantee will be treated as a contingent liability for the Company. In the event of failure on the part of Phixen SAS in repaying the same to MUFG Bank, the Company has to repay the draw-down amount along with the interest to the MUFG Bank.